Related Experiment Videos

The hypertension-lipid connection: insights into the relation between angiotensin II and cholesterol in atherogenesis

Carlos M Ferrario1, Ronald Smith, Pavel Levy

  • 1Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157, USA. cferrari@wfubmc.edu

The American Journal of the Medical Sciences
|January 30, 2002
PubMed

Insights

Statins manage coronary heart disease by affecting lipid metabolism. Emerging research suggests non-lipid effects of statins and angiotensin II may offer combined benefits for hypertension management.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Abnormal lipid metabolism is key in atherosclerosis, with statins (hydroxymethylglutaryl coenzyme reductase inhibitors) being a primary treatment for coronary heart disease.
  • Emerging research highlights the vascular renin-angiotensin system's role in early endothelial dysfunction and inflammation, crucial steps in atherogenesis.

Purpose of the Study:

  • To discuss the biological effects of statins and angiotensin II in atherogenesis.
  • To explore potential links between statins and angiotensin receptor blockers.
  • To hypothesize about the additive effects of combined statin and renin-angiotensin system blocker therapy in hypertensive patients.

Main Methods:

  • Review of clinical data and experimental studies.
  • Discussion of biological effects of statins and angiotensin II.
  • Assessment of commonalities in non-lipid actions on atherogenesis.

Main Results:

  • Statins are established treatments for coronary heart disease, primarily through lipid metabolism modulation.
  • The vascular renin-angiotensin system plays a role in early atherogenesis.
  • Non-lipid effects of statins and angiotensin II share commonalities in influencing atherogenesis.

Conclusions:

  • Dyslipidemia may impact blood pressure control in hypertensive individuals.
  • Combined therapy with statins and renin-angiotensin system blockers may offer additive benefits for managing hypertension.

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...